Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of ailse thyroid.
Dúirt Eisai go mbeidh Lenvima ina chaighdeán nua le haghaidh cóireáil chliniciúil ar ailse thyroid nach féidir a ghlacadh. Tá an tionscal an-dóchasach faoi Lenvima, agus táthar ag súil go dtiocfaidh an druga chun bheith ina bó airgid nua do Eisai, le díolacháin bhliantúla ag buaicphointe níos mó ná $ 1 billiún.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved meall volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Faoi láthair, cé gur féidir an chuid is mó de na cineálacha ailse thyroid a chóireáil, níl mórán roghanna cóireála ann nuair a éiríonn sé níos measa. Is é ailse thyroid difreálach (DTC) an meall thyroid urchóideach is coitianta, agus tá méadú tagtha ar a mhinicíocht le blianta beaga anuas.
Is inhibitor il-receptor tyrosine kinase (RTK) ó bhéal é Lenvatinib le modh ceangailteach úrscéal. Chomh maith le bac a chur ar RTKanna eile a bhfuil baint acu le hiomadú siadaí agus bealaí comharthaíochta oncogenic, is féidir leis bac a chur go roghnach ar ghníomhaíocht kinase receptor fachtóir fáis endothelial soithíoch (VEGF).
